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Importance of Diagnosing
Hibernating Myocardium:
How and in Whom?*
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Los Angeles, California
Hibernating myocardium (1–3) can be described by the clinical
situation, that is, it is impaired left ventricular (LV) function at
rest that is reversible by revascularization. Hearse (4) has
defined hibernating myocardium as “exquisitely regulated tis-
sue successfully adapting its activity to prevailing circum-
stances.” Initially, the two clinical syndromes diagnosed in
patients with coronary artery disease (CAD) were angina and
myocardial infarction (MI). Subsequently, it was recognized
that these two conditions could be painless, and the syndromes
of unstable angina and non-Q wave MI were also diagnosed.
Hibernating myocardium is one of three myocardial states of
new ischemic syndromes (5) (Fig. 1) and is one of the
myocardial states that may be present in patients in areas of
LV dysfunction at rest (Table 1).
There is a considerable body of evidence (which is progres-
sively increasing) showing that hibernating myocardium is a
result of, and is associated with, reduced myocardial blood flow
(MBF) or reduced myocardial perfusion at rest and that
hibernating myocardium is normalized or improved with in-
creasing MBF, reperfusion or myocardial revascularization
(6,7). Hibernating myocardium, if revascularized, is associated
with a lower cardiovascular event rate (8). Coronary bypass
surgery, if it increases or normalizes MBF, reduces or elimi-
nates the frequency and severity of angina and the need for
pharmacologic treatment (9). Randomized trials in selected
patients have documented better survival in those “assigned
to” coronary bypass surgery than in those “assigned to”
medical treatment in patients with left main CAD; three-vessel
CAD with normal LV function; and two-vessel CAD if one of
the vessels was the proximal left anterior descending coronary
artery (2,10,11). In patients with LV dysfunction at rest,
randomized trials of coronary bypass surgery have shown an
improved survival (2,10), particularly in patients with three-
vessel CAD (12). Complete revascularization is important for
improving the long-term outcome of severely symptomatic
patients with three-vessel CAD and LV dysfunction (13).
Percutaneous transluminal coronary angioplasty has been doc-
umented in randomized trials of selected patients to have
results (both short term and intermediate up to 5 years) similar
to those of coronary bypass surgery (14–17). The conclusions
from these studies were that revascularization was of benefit in
patients with hibernating myocardium and that it was also
needed in selected patients with CAD to improve survival and
the symptomatic state. As a result, the “conventional wisdom”
developed that if patients had LV dysfunction at rest and had
unstable angina or stable chronic angina and left main or
three-vessel CAD, they should undergo revascularization by
interventional techniques, without the need for documenting
the presence and extent of hibernating myocardium.
In the current issue of the Journal, Haas et al. (18) describe
their findings in patients with “advanced” three-vessel CAD
and severe LV dysfunction (LV ejection fraction [LVEF]
#0.35) who underwent coronary bypass surgery. Thirty-five
patients had coronary bypass surgery on the basis of clinical
presentation and angiographic data (group A), and 34 patients
had coronary bypass surgery on the basis of positron emission
tomographic (PET) findings in addition to the clinical presen-
tation and angiographic data (group B). The PET findings
included presence of viable myocardium (see later) and sub-
jectively determined the extent of necrosis and viable tissue.
Group B patients had a lower hospital mortality rate (0% vs.
11.4%, p 5 0.04), a lower rate of complicated postoperative
recovery (33% vs. 67%, p 5 0.05), a lower incidence of low
output syndrome (3% vs. 17%, p 5 0.05) and a lower propor-
tion of patients who needed catecholamine support (0% vs.
29%, p 5 0.002). Furthermore, the 1-year survival rate was
better (97 6 8% vs. 79 6 8%, p , 0.01); and, in selected
patients studied postoperatively, the LVEF increased from
26% to 35% (p 5 0.003) in group B, but the change in LVEF
in group A (30% to 34%) was not statistically significant. These
data support the notion that testing for hibernating myocar-
dium is important in determining improved patient outcomes
in patients with three-vessel CAD and severe LV dysfunction
(LVEF # 0.35).
However, there are limitations to the study of Haas et al.
(18), some of which the authors themselves have described: 1)
The study was a retrospective review of the patients, which
means that it is uncertain whether the two groups were
identical, even though there were no statistically significant
differences in the preoperative characteristics that were exam-
ined, and that the patients in this study were a highly select
subgroup; 2) whether the symptomatic state was due to angina
or heart failure, or both, was not well documented; 3) LVEF
was assessed preoperatively by contrast LV angiography and
postoperatively by radionuclide angiography, and only three-
fourths of the surviving patients had postoperative studies
(postoperative LVEF in patients who subsequently died was
not documented); 4) the functional outcome of regional myo-
cardial segments after coronary bypass surgery was not inves-
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tigated; and 5) the extent of “scar” tissue was visually esti-
mated. Other limitations are that 1) wall motion was evaluated
subjectively; and 2) the time lag between assessment of LV
function at angiography and PET studies to assess viability is
not stated.
Other problems relate to recognizing differences between
MBF and assessment of perfusion and criteria for viability. The
authors describe “normal or near-normal blood flow” in some
group B patients; however, they did not actually measure MBF
but subjectively determined tracer uptake of nitrogen-13 am-
monia, which evaluates “perfusion.” Perfusion, determined in
patients, is related to MBF but is not a direct measurement of
MBF. In discussing hypoperfusion or reduced MBF in hiber-
nating myocardium, it needs to be emphasized that LV con-
traction is most importantly related to subendocardial MBF
(6,19,20). It is known from experimental studies that 1) when
subendocardial MBF falls by only 10% to 20%, regional
myocardial function is severely impaired (19,20); and 2) there
is a sensitive coupling between subendocardial MBF and
function in conscious dogs with acute myocardial ischemia
(19). No technique currently available can measure subendo-
cardial MBF in humans. Even PET, which measures transmu-
ral MBF, at the present time cannot determine subendocardial
MBF in humans because it lacks sufficient spatial resolution.
However, if transmural MBF is reduced, a greater reduction in
subendocardial MBF is present (6). Experimental studies
indicate that when transmural MBF falls by ;22%, subendo-
cardial MBF falls by ;38 to 48% (20,21). Haas et al. (18) also
assessed myocardial viability, but there are several different
myocardial states that are viable (Table 2). Thus, the question
is, What myocardial states are present in their group B patients
who had viable myocardium in areas of LV dysfunction? One
subset in group B is labeled “mismatch” by PET (22), defined
in the study as “reduced blood flow with preserved or increased
FDG [fluorine-18 fluorodeoxyglucose] uptake”; this indicates
that hibernating myocardium was present in areas of wall
motion abnormalities in these patients. The other subset in
group B is labeled “normal” by PET, which was defined in the
study as “normal or near-normal blood flow” (not defined by
the authors) with normal or increased F-18 FDG uptake. It
is uncertain what is normal or near-normal blood flow be-
cause the authors have actually evaluated tracer uptake of
nitrogen-13 ammonia by subjective means (see earlier). For
example, 1) can one reliably detect a 10% to 20% reduction in
subendocardial MBF by subjective evaluation of transmural
tracer uptake?; and 2) comparison of tracer uptake evaluated
subjectively in areas of LV dysfunction with other areas in
patients with severe multivessel CAD may be problematic, at
least in some patients (6). The number of patients in group B
who had mismatch or a normal pattern is not stated, and
details for each individual patient in group B are not given (6),
as was done recently by Sun et al. (23). Therefore, there is
uncertainty about the myocardial state in the subset of group B
patients labeled “normal” (6). Nevertheless, the study of Haas
et al. (18) is important because it provides some data that
question the conventional wisdom. At first, a challenge to the
conventional wisdom may seem inappropriate and unreason-
able. However, LV dysfunction at rest can result from a variety
of myocardial states (Tables 1 and 2), and studies that docu-
mented an improvement in survival with coronary bypass
surgery in patients with LV dysfunction (see earlier) did not
study or document the mechanism or mechanisms by which
Abbreviations and Acronyms
ALCAPA 5 anomalous left coronary artery from pulmonary artery
CAD 5 coronary artery disease
F-18 FDG 5 fluorine-18 fluorodeoxyglucose
LV 5 Left ventricle, left ventricular
LVEF 5 left ventricular ejection fraction
MBF 5 myocardial blood flow
MI 5 myocardial infarction
PET 5 positron emission tomography (tomographic)
SPECT 5 single-photon emission computed tomography
(tomographic)
Figure 1. Evolution of the various clinical syndromes in patients with
CAD. AMI 5 acute myocardial infarction.
Table 1. Myocardial States Frequently Present in Patients in Areas
of Left Ventricular Dysfunction at Rest
State of
Myocardium LV Dysfunction at Rest
Irreversibly damaged 1 1 1 1 2 2
Viable and at risk
Hibernating 2 1 2 1 1 1
Ischemic on “stress” 2 2 1 1 2 1
LV 5 left ventricular; 1 5 yes; 2 5 no.
Table 2. Areas of Left Ventricular Myocardium That Have
Viable Myocardium
Normal LV function at rest
LV dysfunction on stress
LV dysfunction at rest
Stunned myocardium
Hibernating myocardium
LV 5 left ventricular.
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coronary bypass surgery produced this benefit. The improve-
ment in survival could have been a result of salvage of
hibernating myocardium, prevention of subsequent myocardial
infarction, particularly in areas that were ischemic on “stress,”
or both. The randomized trials of coronary bypass surgery have
not documented a significant reduction of the incidence of
subsequent acute MI, and thus it is possible that an important
mechanism for the improvement in survival with coronary
bypass surgery was the salvage of hibernating myocardium
(3,13). Moreover, studies that have shown a benefit with
coronary bypass surgery in patients with rest LV dysfunction
were associated with operative and late mortality (2,10,12,
13,24–26), which presumably could have been lower if those
undergoing operation had included only patients with a “sig-
nificant” amount of hibernating myocardium as the major
cause of the LV dysfunction, as is suggested by the study of
Haas et al. (18). Therefore, it is reasonable that an assessment
of hibernating myocardium could allow better assessment of
the risks and benefits in patients with LV dysfunction who are
to undergo revascularization (18), as well as allowing better
selection of patients who should undergo revascularization.
This premise is further supported by studies in patients with
severe chronic heart failure and patients being considered for
heart transplantation (27–33). Documentation of hibernating
myocardium in such patients has allowed the choice of appro-
priate therapy—revascularization rather than transplantation
(27,28,31–33).
Diagnostic testing for hibernating myocardium. An impor-
tant question is, Who should undergo diagnostic testing for
hibernating myocardium? It is not possible to provide a
definite answer because we do not know 1) which test or
combination of tests is best, that is, with a very high positive
and negative predictive accuracy, for the diagnosis of hibernat-
ing myocardium. The most commonly used tests for diagnosing
hibernating myocardium are dobutamine echocardiography,
thallium and sestamibi single-photon emission computed to-
mographic (SPECT) myocardial perfusion imaging and PET.
Bonow (34), after a review of published reports, documented
that the predictive accuracies for the three techniques was
83%, 69% and 82%, respectively, for positive test results, and
81%, 90% and 83%, respectively, for negative test results.
However, in an individual center, any two tests may have
similar accuracy (35), and the sensitivity and specificity of tests
can be altered, depending on the criteria used (36). Moreover,
there are few data on the accuracy of these tests in any one of
the several clinical syndromes in which hibernating myocar-
dium has been documented so far (Table 3). Moreover,
frequently the protocol for performing the test or tests is not
standardized, the data obtained are subjectively evaluated and
not quantified, and the standards for assessing the accuracy
may be inadequate. 2) Additional newer tests, for example,
PET imaging with carbon-11 acetate alone or in combination
with other tracers (37–39) and advances with SPECT imaging
(40,41), also need to be evaluated, 3) We cannot reliably
diagnose the amount of hibernating myocardium and the
amount of irreversibly damaged myocardium, although some
initial data are promising (42). Uniform and generally ac-
cepted standards for these tests are needed.
Nevertheless, it is possible to provide some guidelines based
on the assessment and consideration of 1) the severity of LV
dysfunction; 2) the extent and severity of CAD and the state of
the distal coronary arteries; and 3) the clinical syndromes in
which hibernating myocardium has been documented so far
(Table 3).
Patients with normal LV function and those with coronary
arteries that are not suitable for revascularization do not need
to be tested (Table 4). At the present time, transmyocardial
laser revascularization is still on experimental procedure.
Diagnostic testing for hibernating myocardium is needed 1)
in patients known to have significant CAD and in those with
suspected CAD or suspected idiopathic dilated cardiomyo-
pathic who are being considered for heart transplantation; 2)
in all patients with significant CAD and severe LV dysfunction
(i.e., LVEF #0.35); and 3) in all patients with CAD and LV
dysfunction who are asymptomatic or have symptoms due to
heart failure or LV dysfunction or who have only mild or
minimal angina.
If patients do not fit into these subgroups, that is, mainly
patients with mild to moderate LV dysfunction (LVEF 0.36 to
0.49), one may need to consider the clinical syndrome with
which they present. Diagnostic testing is probably not indicated
in patients with unstable angina, that is, angina at rest,
Table 3. Clinical Syndromes in Which Hibernating Myocardium Has
Thus Far Been Documented
Angina
Chronic stable
Unstable
Acute myocardial infarction
Heart failure and/or severe LV dysfunction
ALCAPA
ALCAPA 5 anomalous left coronary artery from pulmonary artery; LV 5
left ventricular.
Table 4. Diagnostic Testing for Hibernating Myocardium*
Usually not needed†
Normal LV function
Coronary arteries not suitable for revascularization
Usually needed†
Suspected CAD/IDCM, being considered for heart transplantation
CAD plus severe LV dysfunction (LVEF #0.35)
CAD plus dysfunction in patients who are asymptomatic or have heart
failure symptoms: mild/minimal angina
Individualize‡
Unstable angina/severe stable angina
Acute MI
ALCAPA
*Only needed in patients with left ventricular dysfunction at rest. †Clinical
judgment may be needed. ‡Clinical judgment frequently needed. CAD 5
coronary artery disease; IDCM 5 idiopathic dilated cardiomyopathy; LVEF 5
left ventricular ejection fraction; MI 5 myocardial infarction; other abbrevia-
tions as in Table 3.
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progressively increasing angina despite medical therapy and
angina #2 weeks after MI, (43) that is, those in Braunwald
classes B and C; II and III (44), and in most patients with
severe, chronic stable angina, because revascularization is
often undertaken in these patients for relief of symptoms.
However, one must recognize that 1) the severity of angina
may not relate to the extent of myocardium at risk, extent and
severity of CAD and LV function (45); 2) in patients with
angina (if one excludes unstable angina), the extent of CAD
and LV function and the extent and severity of ischemia are
predictors of outcome but angina is not (2,46,47); and 3)
documentation of the amount of hibernating myocardium may
allow better assessment of the risks and benefits of revascular-
ization (see above). Post-MI patients pose a more difficult
problem because of the complexity and variety of clinical
situations that may be present. These include the clinical state
of the patient, location of the MI, extent and severity of CAD,
extent and severity of LV dysfunction and the feasibility of
revascularizing all dysfunctional myocardial segments; thus,
the need to revascularize some or all dysfunctional LV seg-
ments may require evaluation by testing for hibernating myo-
cardium. Anomalous left coronary artery from pulmonary
artery (ALCAPA) is a congenital disorder that often presents
with LV dysfunction or heart failure with or without mitral
regurgitation, and the clinical findings may be similar to those
for idiopathic dilated cardiomyopathy. The severe LV dysfunc-
tion and dilation improves or normalizes after surgical correc-
tion (48–54) (Fig. 2). Pathologic studies of transmural myo-
cardial biopsy specimens have shown changes that are those of
“structural adaptation to chronic ischemia” (53) and are
similar to those described in hibernating myocardium. Patients
with ALCAPA should be diagnosed early and should have
early reimplantation of the left coronary artery into the aorta.
Those with severe LV dysfunction may need testing for
hibernating myocardium. In all the above clinical syndromes,
there is a need for clinical judgment. It must also be borne in
mind that in all the above subgroups of patients, assessment of
hibernating myocardium may allow better assessment of the
risks and benefits of revascularization; however, additional
studies are needed that document this premise.
Revascularization for hibernating myocardium. Function
in hibernating myocardium improves or normalizes with revas-
cularization, but the effects of optimal medical therapy have
not been evaluated. Factors to be considered in recommending
revascularization are shown in Table 5. Important factors that
are likely to determine the expected improvement in LV
function and hence patient outcome are an estimate of the
extent of irreversibly damaged myocardium and the extent of
hibernating myocardium (55,56). Haas et al. (18) used three
criteria to recommend revascularization for patients in Group
B, one of which was viable myocardium (see earlier). The other
two were extent of necrosis and viable tissue. Although these
were determined subjectively, it is, nevertheless, an important
direction to pursue in determining whether patients should
undergo revascularization. Additional studies are needed.
Some additional studies that are needed. The need for
large, randomized studies to confirm the finding of Haas et al.
(18), as suggested by the authors, may be premature at this
time (57) because of the limitations of their study. The
predictive accuracy of tests for diagnosis of hibernating myo-
cardium may be inaccurate in 15% to 30% of patients; we do
not know which test or combinations of tests is best for
diagnosis of hibernating myocardium in each clinical syndrome
Figure 2. Preoperative (Pre-op) and postoperative LV end-diastolic
volume (EDV) index (left) and LV ejection fraction (EF) (right) in
five patients 2 to 8.5 years old who underwent surgical correction for
ALCAPA. d 5 days after operation; mos 5 months after operation;
CM 5 data from patients with IDCM at the author’s institution.
Reproduced, with permission, from Rein et al. (49).
Table 5. Some Factors to Be Considered in Clinical Decision
Making When Considering Revascularization for
Hibernating Myocardium
Suitability of coronary arteries for revascularization
Severity of LV dysfunction
Symptoms, especially angina
Extent of irreversibly damaged myocardium
Extent of HM
Risks of revascularization
Estimate of LV functional recovery after revascularization
HM 5 hibernating myocardium; LV 5 left ventricular.
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in which hibernating myocardium has so far been described;
and we may not have enough data to estimate the number of
patients that may be needed for each clinical syndrome to have
a good chance of obtaining definite answers.
There is a need for 1) well designed studies that evaluate
the predictive accuracy of various tests, singly or in combina-
tion, for diagnosing hibernating myocardium in the different
clinical syndromes; 2) well designed studies that evaluate the
risks and benefits of revascularization after testing for hiber-
nating myocardium in each clinical syndrome; 3) well designed
studies that reproducibly and accurately quantitate the amount
of irreversibly damaged myocardium and hibernating myocar-
dium; and most importantly 4) studies that evaluate whether
optimal medical therapy by current standards is of benefit in
hibernating myocardium. At such time, one can determine
whether prospective, randomized trials are needed. If it is
determined that randomized trials are necessary, then a well
designed trial or trials can be initiated, keeping in mind that
outcomes may be different for the different clinical syndromes
(Table 3).
Addendum. After this editorial was submitted, Pagley et al.
(58) documented, by a retrospective review of 70 patients
undergoing coronary bypass surgery for “ischemic cardiomy-
opathy,” that 33 patients with a myocardial viability index
.0.67 (determined by thallium-201 scintigrams) had a signifi-
cantly better short- and long-term cardiac event-free survival
(p 5 0.019) than 37 patients with a viability index #0.67.
The two subgroups were similar with regard to age, gender,
presenting clinical syndrome, electrocardiogram, hemody-
namic variables, number of diseased coronary arteries and
LVEF. The viability index was the only independent predictor
of a 3-year survival free of a cardiac event. Thus, this study also
documents the importance of diagnosing the presence and
extent of hibernating myocardium.
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